JAB-30300 / Jacobio Pharma - LARVOL DELTA

Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S. (PRNewswire) - "Jacobio Pharma...today announced it received IND (Investigational New Drug) approval of its self-developed drug JAB-30300 (P53 Y220C activator) from the FDA of the U.S. Jacobio plans to initiate a Phase I/IIa advanced solid tumors clinical trial in the U.S., to evaluate safety and efficacy of JAB-30300. Jacobio also plans to submit IND in China, and will conduct clinical studies once receives the IND approval."

IND • Solid Tumor

Jacobio Pharma Announces 2023 Interim Results (PRNewswire) - "Development of pre-clinical stage products: (i) JAB-23400 (KRASmulti inhibitor): Preclinical data was released at the annual meeting of the AACR in April 2023. The IND application is expected to be submitted in the first half of 2024; (ii) JAB-30300 (P53 Y220C corrector): JAB-30300 is an orally bioavailable small molecule activator for the treatment of patients with locally advanced or metastatic solid tumors harboring the P53 Y220C mutation. An IND application will be submitted in the second half of 2023."

IND • Preclinical • Oncology • Solid Tumor

Jacobio Pharma Announces 2022 Annual Results (PRNewswire) - "Jacobio has submitted the IND applications of JAB-BX300 (LIF mAb) to the NMPA in January 2023. The IND applications of JAB-23400 (KRASmulti inhibitor), JAB-30300 (P53 Y220C corrector) and JAB-26766 (PARP7 inhibitor) will be submitted this year."

New trial • Oncology